A Randomized Phase II Study Of CMF Alone And In Combination With Anti c-erbB2 Antibody (Herceptin) In Women With c-erbB2 Positive Metastatic Breast Cancer

Trial Profile

A Randomized Phase II Study Of CMF Alone And In Combination With Anti c-erbB2 Antibody (Herceptin) In Women With c-erbB2 Positive Metastatic Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2013

At a glance

  • Drugs Trastuzumab (Primary) ; Cyclophosphamide; Fluorouracil; Methotrexate
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Feb 2010 Planned number of patients changed from 66 to 90 as reported by Roche record.
    • 17 Oct 2009 Status changed from active, no longer recruiting to completed as reported by Roche record.
    • 08 Feb 2009 Last checked against Roche record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top